Horizon Investments LLC Makes New Investment in Haemonetics Corporation $HAE

Horizon Investments LLC acquired a new position in shares of Haemonetics Corporation (NYSE:HAE) in the fourth quarter, Holdings Channel.com reports. The firm acquired 29,923 shares of the medical instruments supplier’s stock, valued at approximately $2,398,000.

A number of other large investors also recently added to or reduced their stakes in the stock. New York State Teachers Retirement System raised its position in Haemonetics by 12.1% during the fourth quarter. New York State Teachers Retirement System now owns 55,888 shares of the medical instruments supplier’s stock worth $4,479,000 after acquiring an additional 6,043 shares during the period. Jennison Associates LLC raised its position in Haemonetics by 11.9% during the fourth quarter. Jennison Associates LLC now owns 12,103 shares of the medical instruments supplier’s stock worth $970,000 after acquiring an additional 1,290 shares during the period. Cardinal Capital Management raised its position in Haemonetics by 1.5% during the fourth quarter. Cardinal Capital Management now owns 22,442 shares of the medical instruments supplier’s stock worth $1,799,000 after acquiring an additional 321 shares during the period. M&T Bank Corp raised its position in Haemonetics by 31.0% during the fourth quarter. M&T Bank Corp now owns 6,154 shares of the medical instruments supplier’s stock worth $494,000 after acquiring an additional 1,457 shares during the period. Finally, Peregrine Capital Management LLC acquired a new position in Haemonetics during the fourth quarter worth $2,293,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Trading Up 0.6%

Shares of HAE opened at $55.64 on Wednesday. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $87.32. The firm has a 50-day moving average price of $59.85 and a 200 day moving average price of $66.63. The firm has a market capitalization of $2.59 billion, a P/E ratio of 15.33, a P/E/G ratio of 1.08 and a beta of 0.53.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The firm had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. During the same quarter in the prior year, the firm posted $1.19 earnings per share. Haemonetics’s quarterly revenue was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Sell-side analysts forecast that Haemonetics Corporation will post 4.95 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Citigroup dropped their target price on shares of Haemonetics from $75.00 to $70.00 and set a “neutral” rating for the company in a report on Wednesday, March 11th. BTIG Research reaffirmed a “buy” rating and set a $88.00 target price on shares of Haemonetics in a report on Friday, February 6th. Barrington Research set a $94.00 target price on shares of Haemonetics in a report on Friday, February 6th. Finally, Robert W. Baird set a $81.00 target price on shares of Haemonetics in a report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and a consensus price target of $82.78.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.